Ceftazidime-Avibactam for Aspiration Pneumonia

Indications and Coverage

The American Thoracic Society recommends that ceftazidime-avibactam is not specifically indicated for aspiration pneumonia, which typically involves anaerobic organisms that ceftazidime-avibactam does not target 1
Ceftazidime-avibactam must be combined with metronidazole when anaerobic coverage is needed, which would be essential in aspiration pneumonia 2, 3

Ceftazidime-avibactam is active against extended-spectrum β-lactamase (ESBL) producing Enterobacterales and certain carbapenemase-producing organisms (KPC and OXA-48) 4
Ceftazidime-avibactam is NOT active against Metallo-β-lactamase (MBL) producing organisms 5
Ceftazidime-avibactam is NOT active against Acinetobacter species, which have intrinsic resistance due to OXA-type carbapenemases not inhibited by avibactam 6
Ceftazidime-avibactam is NOT active against anaerobic bacteria, which are common in aspiration pneumonia 2, 3

For aspiration pneumonia, ceftazidime-avibactam would only be appropriate in healthcare-associated cases with suspected resistant gram-negative pathogens 1, 7
It must be combined with metronidazole to provide anaerobic coverage essential for aspiration pneumonia 2, 3
Treatment duration for pneumonia is typically 7-14 days 7

Using ceftazidime-avibactam for aspiration pneumonia should be reserved for cases where the patient has healthcare-associated aspiration pneumonia 1
Multidrug-resistant gram-negative pathogens are suspected or confirmed 4, 7
Resistance can develop during treatment, particularly with KPC-producing organisms 4, 8

For community-acquired aspiration pneumonia, more appropriate first-line options include ampicillin-sulbactam, amoxicillin-clavulanate, or piperacillin-tazobactam 1
For healthcare-associated aspiration pneumonia with suspected resistant pathogens, carbapenems (imipenem, meropenem, doripenem) provide broader coverage including anaerobes 1, 3
Ceftolozane-tazobactam plus metronidazole may be an alternative, particularly for Pseudomonas infections 2, 3